TABLE 3.
Peptide utilization of opp mutants
| CDM supplement | Utilization by:
|
|||
|---|---|---|---|---|
| 0140J | OppA2− | OppA1− | OppB− | |
| All amino acids | + | + | + | + |
| Minus E | − | − | − | − |
| Minus EV | − | − | − | − |
| WE, EW, EVa | − | − | − | − |
| EVF, VYV | +c | +c | − | − |
| EAMAPK | +b | +b | +b | +b |
| EHIWLMVR | +b | +c | − | − |
| VKEAMAPK | ||||
| LMHVRIEWC | − | − | − | − |
| LMHVRIEWCY | − | − | − | − |
a
Boldface indicates amino acids being tested for utilization from the given peptide or mix of peptides.
b
All strains efficiently utilized glutamic acid from EAMAPK.
c
Wild-type 0140J and the oppA2 mutant efficiently utilized glutamic acid and valine from the peptide mixture. OppA1 and OppB mutants were unable to grow under these conditions.